Literature DB >> 25379849

Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma.

Arnulf H Hölscher1, Uta Drebber, Henner Schmidt, Efriede Bollschweiler.   

Abstract

OBJECTIVES: To evaluate the histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma according to impact on prognosis and to suggest a classification for clinical routine.
BACKGROUND: Measures of histopathologic response to neoadjuvant treatment of esophageal cancer such as Mandard tumor regression grading focus on the effect on the primary tumor. Although lymph node infiltration is of significant prognostic importance, this criterion is mostly not included in the response classifications.
METHODS: A total of 370 patients (89% males, median age: 61 years) with neoadjuvant radiochemotherapy (40 Gy, 5-FU, cisplatin) or chemotherapy (MAGIC or FLOT) for cT3, Nx, M0 esophageal adenocarcinoma were included in the analysis. All patients had undergone transthoracic en bloc esophagectomy, with a median of 27 resected lymph nodes and a R0-resection rate of 92%. Histopathologic regression grading differentiated major or minor response according to less or more than 10% vital cells in the primary tumor. The lymph nodes were classified as ypN0 or ypN+.
RESULTS: From the patients with R0 resection and M0 category, 3 groups with significantly different 5-year survival rates (5-YSR) could be differentiated: 1. Major response and ypN0 (n=100) with 5-YSR of 64% 2. Either major response and ypN+ (n=34) 5-YSR 42% or minor response and ypN0 (n=84) 5-YSR 44%, together 42% 5-YSR 3. Minor response and ypN+ (n=111) and 5-YSR of 18%.
CONCLUSIONS: A combined classification of primary tumor regression and lymph node status in 3 grades represents a simple and reproducible prognostic classification of the effect of neoadjuvant treatment in esophageal adenocarcinoma.

Entities:  

Mesh:

Year:  2014        PMID: 25379849     DOI: 10.1097/SLA.0000000000000964

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

Review 1.  Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher; Matthias Schmidt; Ute Warnecke-Eberz
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

2.  Molecular Marker Expression Is Highly Heterogeneous in Esophageal Adenocarcinoma and Does Not Predict a Response to Neoadjuvant Therapy.

Authors:  Nathan W Bronson; Brian S Diggs; Gene Bakis; Kenneth M Gatter; Brett C Sheppard; John G Hunter; James P Dolan
Journal:  J Gastrointest Surg       Date:  2015-09-22       Impact factor: 3.452

3.  Nodal downstaging in esophageal and esophagogastric junction cancer: more important than ever.

Authors:  Andrea Zanoni
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher
Journal:  Ann Transl Med       Date:  2019-09

5.  The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma.

Authors:  D J Crull; M C H Hogenes; R Hoekstra; E M Hendriksen; M J van Det; E A Kouwenhoven
Journal:  Ann Surg Oncol       Date:  2022-01-29       Impact factor: 5.344

6.  The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer.

Authors:  David T Pointer; Jordan A McDonald; Samer A Naffouje; Rutika Mehta; Jason B Fleming; Jacques P Fontaine; Gregory Y Lauwers; Jessica M Frakes; Sarah E Hoffe; Jose M Pimiento
Journal:  J Surg Oncol       Date:  2022-05-16       Impact factor: 2.885

Review 7.  [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences].

Authors:  I Gockel; F Lordick; O Lyros; N Kreuser; A H Hölscher; C Wittekind
Journal:  Chirurg       Date:  2020-01       Impact factor: 0.955

8.  Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma.

Authors:  Patrick J McLaren; Anthony P Barnes; Willy Z Terrell; Gina M Vaccaro; Jack Wiedrick; John G Hunter; James P Dolan
Journal:  Am J Surg       Date:  2017-03-27       Impact factor: 2.565

9.  Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.

Authors:  Saurabh Singhal; Harit Kapoor; Saravanan Subramanian; Devendra K Agrawal; Sumeet K Mittal
Journal:  J Gastrointest Cancer       Date:  2019-12

10.  Factors Predicting Effectiveness of Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.

Authors:  Yu Ohkura; Masaki Ueno; Toshiro Iizuka; Shusuke Haruta; Tsuyoshi Tanaka; Harushi Udagawa
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.